Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.



To participate or refer a patient, call 954-366-0277; Ext 120 – Jorge, Ext 121 – Rebecca, Ext 124 – Lucy.

Clinical Coordinators: Jorge Riveros, IMG, CCRC • Rebecca Nembhard, CCRC • Lucy Vargas, MA, CRC

Lilly: Trailblazer 3-AACM Preclinical Memory Loss – Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of Donanemab in Preclinical Alzheimer’s Disease for people 55-80 years of age, not yet diagnosed with memory problems.

Jazz: EveresT Essential Tremor – A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults with Moderate to Severe Essential Tremor for people 18-80 years of age.

Sage: Essential Tremor – A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor in adults with mild to moderate bilateral tremor for at least 3 years. Ages 18-80.

Biogen Envision: Alzheimer’s Disease – A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease, ages 60-85.


To participate or refer a patient Call 954-475-8171, ext 146 (Maria) or ext 138 (Barbara)

Clinical Coordinators: Maria Gonzalez, RMA, CCRC and Barbara Mota, RMA, CRC

Takeda: Parkinson’s Disease-A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral TAK-071 in Parkinson’s patients with Cognitive Impairment and an Elevated Risk of Falls for people 40-75 years of age.

Axsome-Alzheimer’s with Agitation: A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’s Type

Cassava: Alzheimer’s Disease – A Phase 3, Double-blind, Pacebo controlled  52-Week study evaluating the safety and efficacy of Simufilam 100 mg tablets in subjects with Mild to Moderate Alzheimer’s Disease in patients age 50-87

Axsome: Migraine – An open label, multidose evaluation of the efficacy and safety of AXS-07 (Meloxican and Rizatriptan) for the Acute treatment of Migraine in adult with an inadequate response to oral CGRP inhibitors. Patients over 18 years of age.

Axsome: Alzheimer’s with Agitation ADVANCE-2 – A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer’s Disease Agitation for 6 weeks, followed by an Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects with Dementia of the Alzheimer’s Type ages 65-90.


To participate or refer a patient –Call 954-475-8171 Ext 134 (Michele)

Clinical Coordinators: Michele Fistel, LPN, CCRC

Sanofi- Gemini 2: Relapsing MS— (SPMS or RRMS) A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 2). Participants must be 18-55 years old.

Novartis: OLIKOS--Relapsing MS (SPMS or RRMS) A 12 month, single-arm, multi-center study to explore maintained efficacy with ofatumumab therapy in patients with relapsing Multiple Sclerosis who discontinue intravenously delivered anti-CD20 monoclonal antibody (aCD2mAb) therapy (Ocrelizumab or Rituximab) Participants must be 18-55 years old.

Novartis-COMB157GUS16: An open-label multicenter study to assess response to COVID-19 vaccine in participants with multiple sclerosis treated with ofatumumab 20 mg subcutaneously

Novartis: COMB157GUS12 – An open-label multicenter study to assess response to influenza vaccine in participants with multiple sclerosis treated with ofatumumab 20 mg subcutaneously for people 18-55 years of age.

Sanofi: Secondary Progressive Non-Relapsing MS – A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study comparing SAR442168 to Placebo in Participants with nonrelapsing Secondary Progressive Multiple Sclerosis (HERCULES)